Gene therapy for primary immunode!ciency diseases: where are we now?

Reflection for the undergraduate on writing in the portfolio: where are we now and where are we going?

Introduction: The portfolio can be seen as a tool for assessmentof a variety of learning activities that differ in content, usage, andassessment. The portfolio not only meets the learner’s educationalneeds but also the political and public reassurance demand thatthe health professional has achieved the required competency ofthe curriculum that allows him or her to practice safely with orwithout...

Molecular Targets for Endometriosis Therapy: Where We Are and Where We Are Going?

N;

Glaucoma, Stem Cells, and Gene Therapy: Where Are We Now?

Glaucoma is the second most common cause of blindness, affecting 70∼80 million people around the world. The death of retinal ganglion cells (RGCs) is the main cause of blindness related to this disease. Current therapies do not provide enough protection and regeneration of RGCs. A novel opportunity for treatment of glaucoma is application of technologies related to stem cell and gene therapy. I...

Molecular Targeted Therapy for Hepatocellular Carcinoma: Where Are We Now?

Behavior therapy for obesity: where are we now?

PURPOSE OF REVIEW To describe the short-term and long-term results of lifestyle modification for obesity. RECENT FINDINGS Randomized controlled trials, which compared different diet and activity interventions were reviewed. Studies that investigated the efficacy of new technologies to provide lifestyle modification, such as web-based delivery, also were examined. SUMMARY In general, compreh...